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This commentary deals with a recent paper1 that
reported efficient inhibition of hepatitis C virus
in infected chimpanzees by an artificial DNA
molecule that blocked the cellular miRNA-122
cofactor.
Viruses Utilize Diverse Cellular
Cofactors, and Hepatitis C Virus Uses
MicroRNA
Viruses are intracellular parasites that can appro-
priate host cell functions to support their prolif-
erative replication cycle. All virologists are used
to the idea that viruses interact with specific cel-
lular proteins to execute diverse steps of their re-
plication cycle. In fact, this microbe-host interplay
starts on the outside of the cells where viruses
bind to a specific cell-surface receptor protein.
These receptors are obvious targets for the design
of antiviral drugs, exemplified by the small mol-
ecule entry inhibitor maraviroc that binds to 
and blocks the C-C chemokine receptor type 5 of 
human immunodeficiency virus 1 (HIV-1).2 Once
enter the cell, viruses and their molecular com-
ponents interact with diverse protein cofactors to
support the replication cycle. Recent RNA inter-
ference (RNAi)-mediated screening has indicated
that a virus can abuse many cellular cofactors for
their own purpose.3 The interaction with the cel-
lular protein cofactors is mediated either by viral
proteins or the viral DNA/RNA genome. Viruses
might also probe other cellular molecules as can-
didate cofactors. For instance, retroviruses form a
close alliance with a specific cellular tRNA mole-
cule that acts as primer of reverse transcription.4
More recently, it has been demonstrated conclu-
sively that hepatitis C virus (HCV) uses the cellu-
lar microRNA (miRNA)-122 as specific cofactor,
which plays an important role in the viral repli-
cation cycle.5
HCV–miR-122 Link
miRNAs are transcripts of 21–23 nucleotides that
regulate the expression of about 30% of all hu-
man protein-coding genes. They act by binding
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to the 3’-untranslated region (3’-UTR) of mRNAs,
which leads to degradation of the mRNA or inhi-
bition of its translation. Two binding sites for
miR-122 have been found in the RNA genome 
of HCV, but in the 5’-UTR and not the 3’-UTR.
Further studies have indicated that, much to the
investigators’ surprise, binding of miR-122 to
HCV RNA stimulates virus replication.5,6 Thus,
HCV replication is reduced significantly in cells
that lack the miR-122 cofactor. The requirement
of miR-122 for HCV replication suggests that this
miRNA could be a target for therapeutic antiviral
intervention.
The miR-122 molecule is specifically and
highly expressed in the liver and has been linked
to cholesterol regulation and lipid metabolism.
Follow-up molecular studies have indicated that
miR-122 interacts with the viral RNA genome to
enhance the process of translation.7 The miR-122
has also been proposed to trigger a riboswitch
mechanism in the viral RNA, which represents 
a novel mechanism of miRNA action.8 Although
one would expect that other viruses will also likely
have adopted cellular miRNAs as cofactors, the
HCV-miR122 case is still unique at this time. Per-
haps the proposed interaction between the HIV-
1 genome and several cellular miRNAs controls
latency of the integrated proviral DNA,9 which
could represent a survival strategy for the virus.
In a broader sense, there are many virus–miRNA
links,10–12 including virus-encoded miRNAs,13
and the use of artificial miRNA-like molecules in
antiviral therapeutic approaches.14,15
Current Therapeutic Approach
One hundred and seventy million people are in-
fected with HCV, and there is an urgent need for
curative therapy. HCV replicates in the liver and
infected persons are at greatly increased risk of
developing liver failure and hepatocellular car-
cinoma. Current therapy of chronic hepatitis C
infection consists of the immune modifier pegy-
lated interferon α and ribavirin, which achieves a
sustained virological response in only half of the
patients, and is associated with severe side effects.
Many small-molecule virus inhibitors are in vari-
ous stages of clinical development. These drugs
target diverse viral functions such as the viral
protease and polymerase, with two protease in-
hibitors currently being tested in phase 3 clinical
trials (Telaprevir from Vertex and Boceprevir
from Schering). Novel therapeutic strategies in-
clude the use of double-stranded RNA molecules
to induce an antiviral response, by instructing the
cellular RNAi mechanism.16 Finally, no effective
HCV vaccines are currently available. This sets
the stage for targeting the miR-122 cofactor as a
novel antiviral strategy.
Antisense Inhibitor of miR-122
The insight that HCV requires miR-122 for repli-
cation has led Santaris Pharma, a biotech com-
pany in Denmark, to develop a candidate drug in
the form of an antisense oligonucleotide that
binds to miR-122, thus blocking its function.
This DNA molecule has been modified as phos-
phorothioate and the so-called locked nucleic acid
oligonucleotide conformation to increase its sta-
bility in serum. This drug candidate, SPC3649,
was first tested in mice and African green mon-
keys, although these species cannot be infected
with HCV.17 The drug significantly decreases total
plasma cholesterol levels when administered as
an intravenous bolus (up to 10 mg/kg every other
day). In a recent study,1 the drug was tested in
four chimpanzees that were chronically infected
with HCV at the Southwest Foundation for Bio-
medical Research in Texas, United States. After
obtaining baseline measurements, the animals
were treated once weekly with a low or high dose
of the antisense molecule (1 or 5 mg/kg) for 12
weeks, followed by a 17-week drug-free follow-
up. A very robust decline in the viral load of
about 350-fold was measured for the high-dose
group of two animals. A more variable and mod-
est suppressive effect on viremia was seen in the
two low-dose animals. A prolonged therapeutic
effect was noticed after therapy was stopped,
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which was likely caused by the increased serum
stability of the modified oligonucleotide. Given
the high stability and good pharmacokinetic
properties of SPC3649, a low or less frequent
dosing regimen could be employed after viral
suppression is achieved by an initial high-dose
treatment. Histological analysis of liver biopsies has
demonstrated improvement of HCV-induced liver
pathology. Overall, the results imply that miR-122
is also essential for HCV replication in vivo.
Therapeutic Options
These results form a proof of principle of the pro-
posed miRNA-targeting therapy. No control DNA
oligonucleotide was included (e.g. with a scram-
bled sequence), therefore, one should remain cau-
tious because sequence-specificity of drug action
has not been demonstrated in the chimpanzee
model. Conversely, the Santaris team has been
able to demonstrate the formation of SPC3649–
miR122 duplexes in the liver. In fact, this duplex
formation resulted in a 300-fold reduction in the
level of free miR-122. Importantly, the study did
not reveal any signs of viral resistance. The virus
did not rebound during therapy, and deep se-
quencing of the viral population did not reveal
any suspected mutations in the 5’-UTR of the HCV
RNA genome, to which miR122 is supposed to
bind. In fact, this high barrier to resistance could
be the greatest promise of approaches that target
cellular cofactors, compared to antiviral strate-
gies that target the virus itself. Viral targeting in-
evitably leads to resistance, usually by one or a
few point mutations in the viral target.18 How-
ever, it seems much more difficult for viruses to
switch from usage of one to another cofactor, or
to evolve an alternative molecular mechanism
that does not depend on such a cofactor.
Safety Issues
As miR-122 is not just expressed in the liver 
to accommodate HCV replication, one wonders
about the effect of miR-122 silencing on cellular
gene expression. Many cellular mRNAs, including
some cancer-related ones, contain miR-122 bind-
ing sites in the 3’-UTR and might be regulated by
miR-122. miR-122 is believed to be involved in
the regulation of cholesterol, fatty acid, and lipid
metabolism. Although too early to conclude, this
could provide an additional benefit as reduced
plasma cholesterol has been measured in studies
with African green monkeys.17 No adverse effects
were noticed in the chimpanzee studies. In fact,
Santaris already have completed a phase 1 trial of
a single SPC3649 dose in healthy volunteers, and
the company has begun a second phase 1 study
that involves multiple doses of the drug. To avoid
long-term usage of such drugs, it is important to
find a drug regimen that facilitates viral knock-
down and subsequent clearance by the human im-
mune system. Such SPC3649-containing regimens
could either replace interferon or be combined
with current treatments. A potential complicating
factor is the recent surprise finding that the miR-
122 level is decreased significantly in individuals
with HCV, who respond poorly to interferon
therapy.19 Perhaps most importantly, conserva-
tion of both miR-122 binding sites in all HCV
variants suggests that a miR-122-targeting ther-
apy will be effective for all HCV genotypes.
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